AR080167A1 - Macrociclos como inhibidores del factor xia - Google Patents

Macrociclos como inhibidores del factor xia

Info

Publication number
AR080167A1
AR080167A1 ARP110100435A AR080167A1 AR 080167 A1 AR080167 A1 AR 080167A1 AR P110100435 A ARP110100435 A AR P110100435A AR 080167 A1 AR080167 A1 AR 080167A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
independently selected
nhco2
conh
Prior art date
Application number
Other languages
English (en)
Inventor
James R Corte
Tianan Fang
Carl P Decicco
Donald J P Pinto
Karen A Rossi
Zilun Hu
Yoon Jeon
Joanne M Smallheer
Yufeng Wang
Wu Wang
Mimi L Quan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR080167A1 publication Critical patent/AR080167A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D225/00Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Estos compuestos son inhibidores selectivos del Factor XIa o inhibidores duales de fXIa y calicreína de plasma. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) o un estereoisomero, un tautomero, una sal farmacéuticamente aceptable o un solvato del mismo, en la que: el anillo A es independientemente un carbociclo C3-10 o un carbociclo de 5 a 10 miembros que comprende: átomos de carbono y 1 - 4 heteroátomos seleccionados de entre N, NH, N(alquilo C1-4), O y S(O)p; el anillo B es independientemente un anillo de benceno o un heteroarilo de 5 a 6 miembros que comprende: átomos de carbono y 1 - 4 heteroátomos seleccionados de entre N, O y S(O)p; el anillo C es independientemente un anillo de benceno o un heterociclo de 5 a 10 miembros que comprende: átomos de carbono y 1 - 4 heteroátomos seleccionados del N, NH, N(alquilo C1-4), O y S(O)p; L1 se selecciona independientemente del grupo constituido por: un enlace, -CHR5-, -CHR5CHR5-, -CR5=CR5-, -CsC-, -OCH2-, -CHR5NH-, -CH2O-, -SCH2-, -SO2CH2-, -CH2NH- y -CR5R5-; L se selecciona independientemente del grupo constituido por: alquileno C3-8, alquenileno C3-8 y alquinileno C4-8, en el que dichos alquileno, alquenileno y alquinileno están sustituidos con 0 - 2 R7 y opcionalmente uno o varios de los átomos de carbono de dichos alquileno y alquenileno pueden estar reemplazados por O, S, NH, N(alquilo C1-4), CO, CONH, NHCO, OCONH, NHCO2, -NHCONH-, SO2NH, NHSO2, CON(alquilo C1-4) o N(alquilo C1-4)CO; Y se selecciona independientemente del grupo constituido por: CH2, CH(alquilo C1-4), C(alquilo C1-4)2, CO, O, S, NH, N(alquilo C1-4), N(CO2(alquilo C1-4)), -N(alquil C1-4)CH2-, -N(CO2(alquil C1-4))CH2-, -N(CH2CO2(alquil C1-4))CH2-, -CONH-, -NHCO-, -CONHCH2-, -CON(alquil C1-4)CH2-, -OCONH-, -OCON(alquilo C1-4)-, -NHCONH-, -SO2NH-, -NHCO2- y -NHSO2-; alternativamente, L-Y es alquileno C3-6-CH=N-; R1, en cada aparicion, se selecciona independientemente del grupo constituido por: halogeno, alquilo C1-6, alcoxi C1-4, alquiltio C1-4, haloalquilo C1-4, OH, OCH2F, OCHF2, OCF3, CN, NH2, NH(alquilo C1-4), N(alquilo C1-4)2, -CO2(alquilo C1-4), -CO(alquilo C1-4), -CH2NH2, -CONH2, -CONH(alquilo C1-4), -OCH2CO2H, NHCO(alquilo C1-4), -NHCO2(alquilo C1-4), -NHSO2(alquilo C1-4), -SO2NH2, -C(=NH)NH2 y fenilo sustituido con 0 - 2 Ra; R2 es independientemente un heterociclo de 5 a 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados del N, NH, N(alquilo C1-4), O, y S(O)p, en el que dicho heterociclo está sustituido con 0 - 2 R2a; R2a, en cada aparicion, se selecciona independientemente del grupo constituido por: halogeno, alquilo C1-4, -CH2OH, alcoxi C1-4, OH, CF3, OCF3, CN, NH2, CO2H, CO2(alquilo C1-4), CO-alquilo C1-4, -CONH2, -CONH(alquilo C1-4), -CON(alquilo C1-4)2, -SO2(alquilo C1-4), -SO2NH2, -SO2NH(alquilo C1-4) y -SO2N(alquilo C1-4)2; R3 se selecciona independientemente del grupo constituido por: H, =O, halogeno, OH, NH2, CN, alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, -CH2OH, CO2H, CO2(alquilo C1-4), -C(O)NH2, -C(O)NH(alquilo C1-4), -C(O)N(alquilo C1-4)2, -CH2CO2H y cicloalquilo C3-6; R4 se selecciona independientemente del grupo constituido por: H y alquilo C1-4; R5, en cada aparicion, se selecciona independientemente del grupo constituido por: H, halogeno, OH y alquilo C1-4; R6, en cada aparicion, se selecciona independientemente del grupo constituido por: halogeno, alquilo C1-4, CN, OH, CF3, CO2H, CO2(alquilo C1-4), -CH2CO2H, (CH2)2CO2H, -CH2CO2(alquilo C1-4), -(CH2)2CO2(alquilo C1-4), NH2, -CH2NH2, -NHCO(alquilo C1-4), -NHCOCF3, -NHCO2(alquilo C1-4), -NHCO2(CH2)2O(alquilo C1-4), -NHCO2(CH2)3O(alquilo C1-4), -NHCO2CH2CH(alquil C1-4)O(alquilo C1-4), -NHCO2(CH2)2OH, -NHCO2(CH2)2NH2, -NHCO2(CH2)2N(alquilo C1-4)2, -NHCO2CH2CO2H, -CH2NHCO2(alquilo C1-4), -NHC(O)NH(alquilo C1-4), NHC(O)N(alquilo C1-4)2 -NHSO2(alquilo C1-4), -SO2NH2, -SO2NH(alquilo C1-4), -SO2NH(CH2)2OH, -SO2NH(CH2)2O(alquilo C1-4), -CONH2, -CONH(alquilo C1-4), -CON(alquilo C1-4)2, -CH2CONH2 y -NHCO2(CH2)0-2R9; R7, en cada aparicion, se selecciona independientemente del grupo constituido por: halogeno, OH, NH2, CH2NH2, haloalquilo C1-4, OCH2F, OCHF2, OCF3, -NH(alquilo C1-4), -N(alquilo C1-4)2, alcoxi C1-4, CH2OH, CH2O(alquilo C1-4), CH2O(CH2)1-4O(alquilo C1-4), CO2H, CO2(alquilo C1-4), CO2(CH2)2O(alquilo C1-4), CO2(haloalquilo C1-4), CO2(CH2)2SO2(alquilo C1-4), CH2CO2H, CH2CO2(alquilo C1-4), CONH2, CONH(alquilo C1-4), CON(alquilo C1-4)2, -OCO(alquilo C1-4), CH2NH(CH2)2O(alquilo C1-4), -CONH(alcoxi C1-4), -CO2(CH2)2O(alquilo C1-4), -CO2(CH2)2N(alquilo C1-4)2, -CONH(CH2)2O(alquilo C1-4), -CONH(CH2)2N(alquilo C1-4)2, -CON(alquilo C1-4)(CH2)2O(alquilo C1-4), -CON(alquil C1-4)(CH2)2N(alquilo C1-4)2, alquilo C1-4, -CONHBn, -CONH(OBn), -(CO)0-1(CH2)0-3-carbociclo C3-6 y -(CH2)0-1-(CO)0-1-(W)0-1-(CH2)0-2-(heterociclo de 4 a 6 miembros que comprende átomos de carbonos y 1 - 4 heteroátomos seleccionados de entre N, NH, N(alquilo C1-4), O y S(O)p); en el que dichos carbociclo y heterociclo están sustituidos con 0 - 2 R8; R8, en cada aparicion, se selecciona independientemente del grupo constituido por: halogeno, OH, CHF2, CF3, alcoxi C1-4, CH2OH, CO2H, CO2(alquilo C1-4), CONH2 y alquilo C1-4; R9 es un heterociclo de 4 a 6 miembros que comprende: átomos de carbono y 1 - 4 heteroátomos seleccionados de N, NH, N(alquilo C1-4), N(CO2(alquilo C1-4)), O y S(O)p; Ra, en cada aparicion, se selecciona independientemente del grupo constituido por: halogeno, OH, CF3, alcoxi C1-4 y alquilo C1-4; W se selecciona independientemente del grupo constituido por: O, NH y N(alquilo C1-4); y p, en cada aparicion, se selecciona independientemente del grupo constituido por: 0, 1 y 2.
ARP110100435 2010-02-11 2011-02-11 Macrociclos como inhibidores del factor xia AR080167A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30342310P 2010-02-11 2010-02-11
US40533810P 2010-10-21 2010-10-21

Publications (1)

Publication Number Publication Date
AR080167A1 true AR080167A1 (es) 2012-03-21

Family

ID=43858008

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100435 AR080167A1 (es) 2010-02-11 2011-02-11 Macrociclos como inhibidores del factor xia

Country Status (22)

Country Link
US (9) US8828983B2 (es)
EP (3) EP2534152B1 (es)
JP (3) JP5844287B2 (es)
KR (2) KR101843542B1 (es)
CN (3) CN107973809B (es)
AR (1) AR080167A1 (es)
AU (1) AU2011215898B2 (es)
BR (1) BR112012019925B1 (es)
CA (1) CA2789622C (es)
CL (1) CL2012002229A1 (es)
CO (1) CO6551666A2 (es)
EA (1) EA020528B1 (es)
ES (2) ES2822130T3 (es)
IL (1) IL221343B (es)
MX (1) MX2012008874A (es)
MY (1) MY162936A (es)
NZ (1) NZ602266A (es)
PE (2) PE20160841A1 (es)
SG (1) SG183153A1 (es)
TW (2) TWI577665B (es)
WO (2) WO2011100402A1 (es)
ZA (1) ZA201206758B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI577665B (zh) 2010-02-11 2017-04-11 必治妥美雅史谷比公司 作為因子xia抑制劑之巨環類
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
PL2766346T3 (pl) 2011-10-14 2017-09-29 Bristol-Myers Squibb Company Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
CN108250199B (zh) * 2012-08-03 2021-07-16 百时美施贵宝公司 二氢吡啶酮p1作为凝血因子xia抑制剂
UY34959A (es) * 2012-08-03 2014-01-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Dihidropiridona p1 como inhibidores del factor xia
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
SI2906551T1 (en) 2012-10-12 2018-05-31 Bristol-Myers Squibb Company CRYSTALINOUS FORMATS OF XIA FACTOR INHIBITOR
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2978751B1 (en) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
JP6401247B2 (ja) * 2013-05-06 2018-10-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung キナーゼ阻害剤としての大員環化合物
US20160257668A1 (en) 2013-10-07 2016-09-08 Merck Sharp & Dohme Corp. Factor XIa Inhibitors
RU2727169C2 (ru) 2013-11-18 2020-07-21 Форма Терапеутикс Инк. Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
NO2760821T3 (es) * 2014-01-31 2018-03-10
HUE040226T2 (hu) * 2014-01-31 2019-02-28 Bristol Myers Squibb Co Makrociklusok heterociklusos P2' csoportokkal XIA faktor inhibitorokként
JP6382997B2 (ja) 2014-02-07 2018-08-29 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物
US9676723B2 (en) 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
US9944643B2 (en) 2014-02-11 2018-04-17 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3134408B1 (en) 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
EP3180317B1 (en) 2014-07-28 2021-04-14 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2016036893A1 (en) * 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
NO2721243T3 (es) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
RU2712268C2 (ru) * 2015-01-20 2020-01-28 Мерк Шарп И Доум Корп. ИНГИБИТОРЫ ФАКТОРА XIa
TWI535452B (zh) * 2015-01-23 2016-06-01 長庚醫療財團法人 使用抗-cd44中和抗體來治療和/或預防心房顫動
EP3310777B1 (en) 2015-06-19 2019-10-09 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
ES2803659T3 (es) * 2015-07-29 2021-01-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor xia que contienen restos alquilo o cicloalquilo p2’
ES2937156T3 (es) * 2015-07-29 2023-03-24 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que llevan un grupo P2' no aromático
CN105085492A (zh) * 2015-09-29 2015-11-25 青岛友诚高新技术有限公司 一种可用于制备治疗冠状动脉粥样硬化药物的化合物及其制备方法、用途
EP3371162B1 (en) * 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
AU2016344476B2 (en) 2015-10-29 2020-08-13 Merck Sharp & Dohme Llc Factor XIa inhibitors
EP3423458A1 (en) 2016-03-02 2019-01-09 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
WO2017172957A1 (en) * 2016-04-01 2017-10-05 Kalyra Pharmaceuticals, Inc. Estrogen receptor modulators
US10143681B2 (en) 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3601267A1 (en) 2017-03-21 2020-02-05 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2019011166A1 (zh) * 2017-07-14 2019-01-17 四川科伦博泰生物医药股份有限公司 大环酰胺化合物及其药物组合物和用途
CN109721613B (zh) * 2017-10-27 2021-07-30 四川科伦博泰生物医药股份有限公司 含季铵离子的大环酰胺化合物及其药物组合物和用途
CN109721539B (zh) * 2017-10-27 2021-07-09 天津药物研究院有限公司 吡唑酰胺类衍生物及其制备方法和用途
CN109867660A (zh) * 2017-12-01 2019-06-11 四川科伦博泰生物医药股份有限公司 含季铵离子的四氢异喹啉酰胺化合物及其药物用途
BR112020016123A2 (pt) 2018-02-07 2021-02-23 eXIthera Pharmaceuticals Inc. compostos e composições terapêuticas
GB201805174D0 (en) * 2018-03-29 2018-05-16 Univ Leeds Innovations Ltd Compounds
EP3781565A1 (en) 2018-04-18 2021-02-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
CN109232259B (zh) * 2018-09-27 2021-05-28 浙江理工大学 一种硝基苯乙酮的制备方法
CN111138366B (zh) * 2018-11-06 2023-03-28 天津药物研究院有限公司 吡唑氨基甲酰类衍生物、及其制备方法和用途
WO2020211781A1 (zh) 2019-04-16 2020-10-22 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
US20220281868A1 (en) 2019-07-23 2022-09-08 Medshine Discovery Inc. Macrocyclic derivatives as factor xia inhibitors
CN113004286B (zh) * 2019-12-20 2022-08-12 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的三环类化合物及其用途
CN113004284B (zh) * 2019-12-20 2022-08-12 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的四环类化合物及其用途
CN113004283B (zh) * 2019-12-20 2022-08-12 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的四环类化合物及其用途
WO2021136390A1 (zh) * 2019-12-31 2021-07-08 上海京新生物医药有限公司 凝血因子XIa抑制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
JPS62103070A (ja) 1985-10-29 1987-05-13 Mitsui Toatsu Chem Inc イソオキサゾリン誘導体および植物生長調節剤
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
TW557297B (en) * 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
WO2000076970A2 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6951840B2 (en) * 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
CH1427415H1 (de) 2001-09-21 2023-12-21 Bristol Myers Squibb Holdings Ireland Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
WO2003106438A1 (en) * 2002-06-18 2003-12-24 The Scripps Research Institute Synthesis of diazonamide "a" core
CN1160358C (zh) * 2002-10-09 2004-08-04 武汉大学 (8s,18s)-1,4,10,13,16-五氮杂三环[16.3.0.04,8]二十一烷-9,17-二酮及其制备方法和用途
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
WO2005014566A1 (en) 2003-08-07 2005-02-17 Bayer Pharmaceuticals Corporation Benzofuran derivatives useful for treating hyper-proliferative disorders
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CN101006063B (zh) * 2004-06-15 2013-07-17 布里斯托尔-迈尔斯斯奎布公司 用作丝氨酸蛋白酶抑制剂的五元杂环类化合物
WO2006076575A2 (en) 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
WO2007047608A2 (en) * 2005-10-14 2007-04-26 Epix Pharmaceuticals, Inc. Fibrin targeted therapeutics
KR20080087817A (ko) * 2005-12-14 2008-10-01 브리스톨-마이어스 스큅 컴퍼니 인자 xia 억제제로서 아릴프로피온아미드,아릴아크릴아미드, 아릴프로핀아미드 또는 아릴메틸우레아유사체
US8466295B2 (en) 2005-12-14 2013-06-18 Bristol-Myers Squibb Company Thiophene derivatives as factor XIa inhibitors
ES2365815T3 (es) * 2005-12-14 2011-10-11 Bristol-Myers Squibb Company Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia.
EP1966141A1 (en) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CN101389613B (zh) * 2005-12-23 2011-10-12 布里斯托尔-迈尔斯.斯奎布公司 用作抗凝血药的大环凝血因子viia抑制剂
CN101495480B (zh) * 2006-05-03 2013-07-10 百时美施贵宝公司 作为降钙素基因相关肽受体拮抗剂的受限化合物
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
AU2007297012B2 (en) * 2006-09-13 2011-12-22 Sanofi-Aventis Tartrate derivatives for use as coagulation factor IXa inhibitors
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
CN101611019A (zh) * 2006-12-20 2009-12-23 百时美施贵宝公司 可用作抗凝血药的大环凝血因子Ⅶa抑制剂
AR067329A1 (es) 2007-06-13 2009-10-07 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
CN101801954B (zh) * 2007-09-20 2013-10-09 Irm责任有限公司 作为gpr119活性调节剂的化合物和组合物
EP2065382A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
GB0800035D0 (en) 2008-01-02 2008-02-13 Glaxo Group Ltd Compounds
CN102026996B (zh) 2008-03-13 2015-01-07 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
TWI577665B (zh) * 2010-02-11 2017-04-11 必治妥美雅史谷比公司 作為因子xia抑制劑之巨環類
TW201311689A (zh) * 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
PL2766346T3 (pl) 2011-10-14 2017-09-29 Bristol-Myers Squibb Company Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
EP3290413B9 (en) 2011-12-21 2020-04-29 ONO Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 3位置換プロリン誘導体
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds

Also Published As

Publication number Publication date
NZ602266A (en) 2014-05-30
US9802939B2 (en) 2017-10-31
US20120041190A1 (en) 2012-02-16
ES2822130T3 (es) 2021-04-29
KR101843542B1 (ko) 2018-03-30
CO6551666A2 (es) 2012-10-31
ZA201206758B (en) 2014-02-26
TWI520965B (zh) 2016-02-11
CL2012002229A1 (es) 2013-01-11
US20160362414A1 (en) 2016-12-15
TW201130847A (en) 2011-09-16
US8940720B2 (en) 2015-01-27
CN102753555A (zh) 2012-10-24
US9079918B2 (en) 2015-07-14
JP6294286B2 (ja) 2018-03-14
BR112012019925A2 (pt) 2021-04-20
WO2011100401A1 (en) 2011-08-18
CN102753555B (zh) 2018-01-12
EP2534154B1 (en) 2020-08-05
PE20121806A1 (es) 2013-01-02
CN102834397B (zh) 2016-02-03
CN107973809B (zh) 2023-06-30
US20200087312A1 (en) 2020-03-19
SG183153A1 (en) 2012-09-27
US9453029B2 (en) 2016-09-27
US20180022753A1 (en) 2018-01-25
PE20160841A1 (es) 2016-09-10
JP2013519679A (ja) 2013-05-30
KR101901545B1 (ko) 2018-09-21
MY162936A (en) 2017-07-31
EP2534154A1 (en) 2012-12-19
US20230058729A1 (en) 2023-02-23
KR20170135981A (ko) 2017-12-08
US20120309960A1 (en) 2012-12-06
CA2789622A1 (en) 2011-08-18
CN102834397A (zh) 2012-12-19
AU2011215898B2 (en) 2016-08-11
EP3786165A1 (en) 2021-03-03
AU2011215898A1 (en) 2012-09-27
BR112012019925B1 (pt) 2022-06-14
US8828983B2 (en) 2014-09-09
EP2534152B1 (en) 2018-05-02
US11136327B2 (en) 2021-10-05
US20150266894A1 (en) 2015-09-24
JP5844287B2 (ja) 2016-01-13
EA020528B1 (ru) 2014-11-28
ES2674745T3 (es) 2018-07-03
EA201270716A1 (ru) 2013-03-29
EP2534152A1 (en) 2012-12-19
CA2789622C (en) 2018-04-03
US20140343276A1 (en) 2014-11-20
IL221343A0 (en) 2012-10-31
US10487086B2 (en) 2019-11-26
US20150112058A1 (en) 2015-04-23
MX2012008874A (es) 2012-08-31
CN107973809A (zh) 2018-05-01
US9745313B2 (en) 2017-08-29
IL221343B (en) 2019-01-31
JP2016102114A (ja) 2016-06-02
WO2011100402A1 (en) 2011-08-18
KR20120134122A (ko) 2012-12-11
TW201605806A (zh) 2016-02-16
JP2013519678A (ja) 2013-05-30
TWI577665B (zh) 2017-04-11
JP5841547B2 (ja) 2016-01-13

Similar Documents

Publication Publication Date Title
AR080167A1 (es) Macrociclos como inhibidores del factor xia
DOP2019000218A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
CO2018010748A2 (es) Agentes antivirales contra la hepatitis b
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
UY37998A (es) Agentes antivirales contra la hepatitis b
ECSP10010254A (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
UY38059A (es) Heterociclos sustituidos como agentes antivirales
AR061238A1 (es) Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c
ES2625256T3 (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
UY30527A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
CO6571891A2 (es) Inhibidores del virus de la hepatitis c.
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
UY37997A (es) Agentes antivirales contra la hepatitis b
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
NI201400023A (es) Derivados de pirrolopirimidina y purina
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
CO6561783A2 (es) Inhibidores del virus flaviviridae
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
AR077765A1 (es) Inhibidores de los virus flaviviridae
AR068466A1 (es) Cianoisoquinolina
UY38383A (es) Heterociclos funcionalizados como agentes antivirales

Legal Events

Date Code Title Description
FC Refusal